Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Phase 1 Suspended
36 enrolled
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Phase 1 Suspended
30 enrolled
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Suspended
53 enrolled
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
Phase 1 Suspended
6 enrolled
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
Phase 1 Suspended
56 enrolled
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Phase 1 Suspended
20 enrolled
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Phase 2 Suspended
70 enrolled
IMPACT
Phase 2 Suspended
120 enrolled
CT0991
Phase 1 Suspended
24 enrolled
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Suspended
20 enrolled
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Phase 1 Suspended
12 enrolled
MATCH
Phase 3 Suspended
60 enrolled
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
Phase NA Suspended
64 enrolled
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Phase 1/2 Suspended
210 enrolled
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Phase 1 Suspended
16 enrolled
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Phase 1 Suspended
9 enrolled
REVEAL
Suspended
272 enrolled
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Phase 1/2 Suspended
222 enrolled
Safety and Efficacy Evaluation of CD19-UCART
Phase NA Suspended
20 enrolled
CLL004
Phase 2 Suspended
120 enrolled
CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation
Phase 1/2 Suspended
20 enrolled
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Phase 1 Suspended
128 enrolled
Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+
Phase 3 Suspended
680 enrolled
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Phase 2 Suspended
15 enrolled
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Phase 1/2 Suspended
120 enrolled
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
Phase 2 Suspended
12 enrolled
Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Phase 2 Suspended
20 enrolled
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Phase 3 Suspended
100 enrolled
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Phase 1 Suspended
95 enrolled